Research Article| Volume 22, ISSUE 4, P781-789, December 1995


      This paper is only available as a PDF. To read, Please Download here.


      Using the previously described approach, I find abdominal myomectomy in general to be a procedure quite comparable with other major pelvic procedures, such as hysterectomy. My postoperative course is associated with a 12% complication rate, the majority of which represents transient febrile morbidity, which resolves quite promptly. In addition, my transfusion rate is 3% or less and my postoperative length of stay is 2 to 3 days. This is consistent with other currently reported series and in my estimation justifies the continued philosophy of offering abdominal myomectomy as a primary treatment for symptomatic uterine fibroids regardless of future childbearing options.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Obstetrics and Gynecology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Altchek A
        Management of fibroids.
        Obstet Gynecol. 1991; 4: 463
        • Bellina JH
        Flap technique ureteroplasty.
        Video Journal of Obstetrics and Gynecology. 1989; 2: 3
        • Benagiano G
        Fibroids: Overview of current future treatment options.
        Br J Obstet Gynaecol. 1992; 99: 18
        • Buttram V
        • Reiter R
        Uterine leiomyomata: Etiology, symptomatology, and management.
        Fertil Steril. 1981; 36: 433
        • Candiani G
        • Fedele L
        • Parazzini F
        • et al.
        Risk of recurrence after myomectomy.
        Br J Obstet Gynaecol. 1991; 98: 385
        • Carlson KJ
        • Nichols DH
        • Schiff I
        Indications for hysterectomy.
        N Engl J Med. 1993; 12: 856
        • Coddington CC
        • Collins RL
        • Shauker TH
        • et al.
        Long-acting gonadotropin hormone-releasing hormone analog used to treat uteri.
        Fertil Steril. 1981; 45: 624
        • DeLancey J
        A modified technique for hemostasis during myomectomy.
        Surg Gynecol Obstet. 1992; 174: 153
        • DeLeon F
        • Peters AJ
        What’s new in adhesion prevention?.
        Contempory Obstetrics and Gynecology. 1994; 1: 15
        • Friedman AJ
        • Rein MS
        • Harrison-Atlas D
        • et al.
        A randomized, placebo-controlled, double-blind study evaluating leuprolide acetate depot treatment before myomectomy.
        Fertil Steril. 1989; 52: 729
        • Garcia CR
        Management of the symptomatic fibroid in women older than 40 years of age.
        Obstet Gynecol Clin North Am. 1993; 20: 337
        • Garcia CR
        • Pfeifer SM
        in: Nichols DH Gynecologic and Obstetric Surgery. Mosby, St. Louis1993: 606
        • Ginsberg E
        • Benson CB
        • Garfield JM
        • et al.
        The effect of operative technique and uterine size on blood loss during myomectomy: A prospective randomized study.
        Fertil Steril. 1993; 60: 956
        • Hutchins F
        Myomectomy after selective preoperative treatment with a gonadotropin releasing hormone.
        J Reprod Med. 1992; 37: 699
        • Lamorte A
        • Lalwani S
        • Diamond MP
        Morbidity associated with abdominal myomectomy.
        Obstet Gynecol. 1993; 82: 897
        • Matta W
        • Stabile I
        • Shaw R
        • et al.
        Doppler assessment of uterine blood flow changes in patients with fibroids receiving the gonadotropin-releasing hormone agonist Buserelin.
        Fertil Steril. 1988; 49: 1083
        • Omu AE
        • Ihejerika I
        • Tabowei G
        Management of uterine fibroids at the University of Benin Teaching Hospital.
        Trop Doct. 1984; 14: 82
        • Parker WH
        • Fu YS
        • Berek JS
        Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma.
        Obstet Gynecol. 1993; 83: 414
        • Reiter R
        • Wagner MD
        • Gambone JC
        Routine hysterectomy for large asymptomatic uterine leiomyomata: A reappraisal.
        Obstet Gynecol. 1992; 79: 481
        • Ross R
        • Pike MC
        • Vessey MD
        • et al.
        Risk factors for uterine fibroids: Reduced risk associated with oral contraceptives.
        BMJ. 1962; 293: 359
        • Rubin IC
        Progress in myomectomy.
        Am J Obstet Gynecol. 1942; 44: 196
        • Rubin IC
        Uterine fibromas and sterility.
        Clin Obstet Gynecol. 1958; 1: 501
        • Smith D
        • Uhlir J
        Myomectomy as a reproductive procedure.
        Am J Obstet Gynecol. 1990; 162: 1476
        • Starks GC
        CO2 Laser myomectomy in an infertile population.
        J Reprod Med. 1989; 33: 184
        • Tulandi T
        • Murray C
        • Guralnick M
        Adhesion formation and reproductive outcome after myomectomy and second-look laparoscopy.
        ACOG. 1993; 82: 213
        • Vollenhoven BJ
        • Lawrence AS
        • Healy DL
        Uterine fibroids: A clinical review.
        Br J Obstet Gynaecol. 1990; 97: 285
        • Wallach EE
        in: Thompson JD Rock AJ Telinde’s Operative Gynecology. ed 7. JB Lippincott, Philadelphia1992: 647
        • Wiskind AK
        • Thompson JD
        Abdominal myomectomy: Reducing the risk of hemorrhage.
        Seminars in Reproductive Endocrinology. 1992; 10: 358